Summit Therapeutics SMMT

$ 18.52 -0.56%

Quarterly report 2024-Q3
added 10-30-2024

Summit Therapeutics Balance Sheet 2011-2024 | SMMT

Annual Balance Sheet Summit Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-65.3 M	-344 M	-69 M	-66 M	-35.2 M	-28.5 M	-35.1 M	-23.2 M	-17 M	-3.35 M	-5.34 M	-3.26 M	-5.14 M
Long Term Debt	3.29 M	2.76 M	1.69 M	75 K	-	-	-	-	-	-	-	-	-
Long Term Debt Current	2.81 M	1.69 M	1.09 M	390 K	471 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	5.71 M	35.6 M	37.7 M	1.05 M	1 M	-	-	322 K	324 K
Total Current Liabilities	20.4 M	38.8 M	25.6 M	19.9 M	13.8 M	-	-	-	-	-	-	-	-
Total Liabilities	125 M	538 M	30.1 M	23 M	22.6 M	62.4 M	51.3 M	5.62 M	6.67 M	3.08 M	2.41 M	2.34 M	2.24 M
Deferred Revenue	-	-	7.94 M	8.37 M	4.43 M	14.2 M	8.64 M	-	-	-	924 K	-	-
Retained Earnings	-993 M	-378 M	-300 M	-211 M	-99.8 M	-115 M	-92.2 M	-67.4 M	-45.6 M	-74.5 M	-61.7 M	-54.7 M	-50.9 M
Total Assets	203 M	664 M	113 M	102 M	78.4 M	76.4 M	47 M	35.7 M	29.2 M	10.9 M	6.91 M	6.12 M	8.06 M
Cash and Cash Equivalents	71.4 M	349 M	71.8 M	66.4 M	63.8 M	12.1 M	-	-	-	-	-	-	-
Book Value	77.7 M	127 M	83.3 M	79.5 M	55.8 M	14 M	-4.37 M	30.1 M	22.5 M	7.85 M	4.5 M	3.78 M	5.82 M
Total Shareholders Equity	77.7 M	127 M	83.3 M	79.5 M	78.9 M	32.2 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Summit Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	4.21 M	5.02 M	5.82 M	3.29 M	3.88 M	4.33 M	2.49 M	2.76 M	2.97 M	1.32 M	1.54 M	1.69 M	896 K	1.15 M	351 K	75 K	75 K	75 K	75 K	422 K	422 K	-	-	1.36 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	64.9 M	147 M	133 M	125 M	119 M	118 M	121 M	538 M	22.1 M	44.4 M	52.1 M	30.1 M	26.4 M	26.1 M	76.4 M	23 M	23 M	23 M	23 M	17.4 M	19.4 M	-	-	82.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	3.23 M	5.1 M	7.94 M	7.51 M	7.14 M	7.42 M	8.37 M	8.37 M	4.52 M	8.37 M	2.62 M	2.62 M	-	-	19.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.15 B	-1.1 B	-1.04 B	-993 M	-957 M	-935 M	-921 M	-378 M	-359 M	-338 M	-321 M	-300 M	-272 M	-253 M	-228 M	-211 M	-211 M	-211 M	-211 M	-158 M	-160 M	-	-	-141 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	503 M	342 M	177 M	203 M	218 M	237 M	255 M	664 M	155 M	95.7 M	116 M	113 M	129 M	146 M	141 M	102 M	102 M	102 M	102 M	96.2 M	96.7 M	-	-	78.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	93.8 M	28.4 M	61.3 M	71.4 M	23.8 M	42.1 M	71 M	349 M	122 M	57.3 M	77.4 M	71.8 M	80.2 M	103 M	102 M	66.4 M	21.3 M	36.4 M	66.4 M	63.8 M	63.8 M	27.2 M	-	28.5 M	-	-	-	35.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	438 M	195 M	44.2 M	77.7 M	99.4 M	120 M	133 M	127 M	133 M	51.3 M	64.4 M	83.3 M	102 M	119 M	64.4 M	79.5 M	79.5 M	79.5 M	79.5 M	78.9 M	77.2 M	-	-	-4.46 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	438 M	195 M	44.2 M	77.7 M	99.4 M	120 M	133 M	127 M	133 M	51.3 M	64.4 M	83.3 M	102 M	119 M	64.4 M	79.5 M	79.5 M	79.5 M	79.5 M	78.9 M	77.2 M	43.6 M	51.2 M	32.2 M	-	-	-	-4.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency